Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
AF, Sawalha; WM, Sweileh; SH, Zyoud; SW, Jabi (2008)
Publisher: Co-Action Publishing
Journal: Libyan Journal of Medicine
Languages: English
Types: Article
Background and Objective: The patient package insert is an important source of drug information. The aim of this study was to evaluate and compare the PPI of the anti-infective agents manufactured in Palestine with the imported equivalents. Method: The selection criteria generated 15 different anti-infective agents available as 36 locally manufactured products and 15 imported equivalents. The design of the patient package insert was evaluated in terms of the number of words used in eight main headings and the presence or absence of certain information regarding nine statements. Results: Inserts of locally manufactured products have significantly fewer words than those of imported products with respect to warnings, dosage and administration, and side effects. The most significant difference was found in the warnings. Moreover, differences were found between inserts of local and imported products in terms of the presence of the nine informative statements. Locally manufactured products did not mention inactive ingredients, clinical pharmacology or date of last revision, but all of them provided information on the use of the drug during pregnancy and lactation and on the duration of therapy. However, in general they provided less information than the imported equivalents. Conclusion: Palestinian authorities and local manufacturers should implement appropriate measures to regulate the quality and quantity of information in the patient package insert of locally produced anti-infective agents. PPI improvement will better direct health practices to the benefit of the patients. Key words: patient package insert, evaluation, Palestine, drug information.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Regner MJ, Hermann F, Ried LD. Effectiveness of a printed leaflet for enabling patients to use digoxin side-effect information. Drug Intell Clin Pharm. 1987; 21(2):200-4.
    • 2. Mottram DR, Reed C. Comparative evaluation of patient information leaflets by pharmacists, doctors and the general public. J Clin Pharm Ther. 1997;22(2):127-34.
    • 3. Gibbs S, Waters WE, George CF. Prescription information leaflets: a national survey. J R Soc Med. 1990; 83(5):292-97.
    • 4. Gibbs S, Waters WE, George CF. The benefits of prescription information leaflets. Br J Clin Pharmacol. 1989; 27(6):723-39.
    • 5. Weitbrecht WU, Vosskamper C. Influence of the drug package information paper on compliance of neurological and psychiatric outpatients. Fortschr Neurol Psychiatr. 2000; 70(4):178-84.
    • 6. Bjerrum L, Foged A. Patient information leaflets--helpful guidance or a source of confusion? Pharmacoepidemiol Drug Saf. 2003; 12(1):55-59.
    • 7. The European Parliament and the Council of the European Union, Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use, Off J Eur Communities L311 (2001), pp. 67-128.
    • 8. EMEA, Compilation of QRD decisions on stylistic matters in product information. Version 9, December 2005. http://www.emea.europa.eu/htms/vet/qrd/qrdreference.htm
    • 9. CMD(h), CMD(h) annotated QRD template for MR/'DC procedures. Based on version 7.2 of the QRD template for CP; revision 3rd October 2006 http://www.hma.eu/uploads/media/QRD_annotated_template_ CMDh_01.pdf (accessed November 9, 2006).
    • 10. FDA, Prescribing Information: Imdicon capsules. (accessed July 14, 2006) http:/www.fda.gov/cder/regulatory/physLabel/Imdicon.pdf
    • 11. Lal R, Kremzner M. Introduction to the new prescription drug labeling by the Food and Drug Administration. Am J Health Syst Pharm. 2007 Dec 1;64(23):2488-94.
    • 12. Fuchs J, Hippius M. Inappropriate dosage instructions in package inserts. Patient Educ Couns. 2007; 67(1-2):157-68.
    • 13. Koo MM, Krass I, Aslani P. Factors influencing consumer use of written drug information. Ann Pharmacother. 2003; 37(2):259-67.
    • 14. TGA, Review of the labelling requirements for medicines consumer-focused labelling-a way forward? http://www.tga.gov.au/docs/pdf/labelrev.pdf (accessed January 27, 2007).
    • 15. Basara LR, Jurgens JP. Patient package insert readability and design. Am Pharm. 1994; NS34 (8):48-53.
    • 16. http://www.moh.ps/en. (2003 mortality report)
    • 17. Gebran N, Al Haidari K. Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia.Ann Saudi Med. 2006;26(3):192-99.
    • 18. Bawazir SA, al-Hassan MI, al-Khamis KI, Abou-Auda HS, Gubara OA. Comparative study of Saudi-marketed products and US drug labeling. DICP. 1991;25(7-8):863-66.
    • 19. Svarstad BL, Mount JK, Tabak ER. Expert and consumer evaluation of patient medication leaflets provided in U.S. pharmacies. J Am Pharm Assoc 2005; 45(4):443-51.
    • 20. Reggi V, Balocco-Mattavelli R, Bonati M, Breton I, Figueras A, Jambert E, Kopp C, Montane E, Rago L, Rocchi F. The International Comparative Study on Drug Information Collaborative Group. Prescribing information in 26 countries. A comparative study. Eur J Clin Pharmacol. 2003; 59(4):263-70.
    • 21. Bernardini C, Ambrogi V, Fardella G, Perioli L, Grandolini G. How to improve the readability of the patient package leaflet: a survey on the use of colour, print size and layout. Pharmacol Res. 2001; 43(5):437-44.
    • 22. Stahl C, Brauer S, Zeitler H, Gulich M. How important is a package insert for drug therapy in ambulatory care? J Public Health. 2006; 14(3):174-77 22 51 42. 46% 60% .2 .4 2% % % The locally produced anti-infective agents are manufactured by four companies (A,B,C,D). The score represents number of statements written in the PPI. Percentage is calculated by dividing total score by the maximal score.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article

Collected from